Latest Content

  • Decentralized Trials: Considerations for Building a New Patient-Centric Model

    Decentralized Trials: Considerations for Building a New Patient-Centric Model

    During the past year, patients around the world waiting for new treatments have taken heart that clinical trials have been ongoing, despite the enormous logistical challenges posed by the...

    Learn More
  • ×

    Let's start a conversation...

    First Name
    Last Name
    Job Title
    Company Name
    Country
    Therapeutic Area Interest - optional
    Tell us how we can help
    Thank you! We'll be in touch soon.
    Error - something went wrong!
  • Decentralized clinical trials- A more patient-centric approach

    Decentralized clinical trials- A more patient-centric approach

    Read More
  • Four Keys to a Smoother Clinical Development Journey

    Four Keys to a Smoother Clinical Development Journey

    Read More
  • Entering a new age of evidence generation: synthetic control models

    Entering a new age of evidence generation: synthetic control models

    Read More
  • Real-world evidence for more efficent, patient-focused trials

    Real-world evidence for more efficent, patient-focused trials

    Read More
  • Innovating for the future of drug development

    Innovating for the future of drug development

    Read More
  • PharmaVOICE RWE Showcase -The RWE Evolution

    PharmaVOICE RWE Showcase -The RWE Evolution

    Read More
  • Six top tips to prepare for the new EU Clinical Trial Regulation

    Six top tips to prepare for the new EU Clinical Trial Regulation

    Read More
  • Jhee Stanford et al-Ethnobridging-Feature-Focus-RR-Feb2021

    Jhee Stanford et al-Ethnobridging-Feature-Focus-RR-Feb2021

    Read More
  • Payer insights for cell and gene therapies2:29

    Payer insights for cell and gene therapies

    It is essential to address the payer landscape very early in development for a product administered once with a lifelong effect, such as a gene therapy. The one-time, front-loaded costs of these treat

    Watch Video
  • CAR-T: A patient’s cell therapy success story7:35

    CAR-T: A patient’s cell therapy success story

    Clinical trials of (CAR) T-cell therapies can present unprecedented enrolment challenges. How can we encourage participation in these trials? Doug Olson, one of the first CAR-T patients treated on a

    Watch Video
  • Regulatory considerations from former FDA regulators

    Regulatory considerations from former FDA regulators

    In this infographic, we’ve compiled some common questions our ex-FDA experts get asked, along with their perspectives.

    Learn More
  • Our latest Cell & Gene Therapy content, all in one place

    Access the hub
  • Creating an effective cell or gene therapy communications strategy

    Creating an effective cell or gene therapy communications strategy

    In this infographic, we have outlined some engagement activities that can enhance your cell or gene therapy development and inspire your stakeholders.

    Learn More
  • Dosing strategies for gene therapies

    Dosing strategies for gene therapies

    In this article, our gene therapy experts at Health Advances, Parexel’s commercial strategy group, outline considerations for competitively positioning your gene therapy.

    Read More
  • Links to videos and COVID blog

    Links to videos and COVID blog

    Read More
  • The Evolving Cell and Gene Therapy (CGT) Sector in China

    The Evolving Cell and Gene Therapy (CGT) Sector in China

    Learn More
  • Case Study Achieving Product Endorsement after a FDA Warning Letter

    Case Study Achieving Product Endorsement after a FDA Warning Letter

    Read More
  • EU Clinical Trial Regulation 536/2014 Factsheet

    EU Clinical Trial Regulation 536/2014 Factsheet

    Read More
  • I Can See More Clearly Now – FDA Issues Needed Guidance on Inspection Policies During COVID-19

    I Can See More Clearly Now – FDA Issues Needed Guidance on Inspection Policies During COVID-19

    FDA has previously made several public statements about its ability to conduct inspections and FDA personnel have also made policy comments in various public forums. Now that this guidance has...

    Learn More
  • Genomics & biomarkers: Answers in the blood2:53

    Genomics & biomarkers: Answers in the blood

    Parexel’s Anita Nelsen, SVP, Translational Medicine and Michelle Hoiseth, Chief Data Officer, Corporate VP speak with Ashley Druckenmiller about caring with her two sons with hemophilia and the benefi

    Watch Video
  • loading
    Loading More...